Equities research analysts at HC Wainwright dropped their Q1 2025 earnings estimates for MoonLake Immunotherapeutics in a ...

Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Iovance Biotherapeutics in a report issued ...

Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.

Fintel reports that on February 26, 2025, HC Wainwright & Co. downgraded their outlook for Geron (NasdaqGS:GERN) from Buy to ...

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...

SoundHound AI's speech recognition model "outperformed" Google and OpenAI during Q4 as it announced a new seven-figure energy ...

Tuesday, Summit Therapeutics plc (NASDAQ:SMMT), currently trading at $18.84, maintained a Buy rating from H.C. Wainwright, with analysts keeping a steadfast $44.00 price target on the stock.

Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...

Minerva Neurosciences Inc (NERV) is expected to report for 4Q. NeuroMetrix Inc (NURO) is expected to report for 4Q. Nikola Corp (NKLAQ) is expected to report for 4Q. Norwegian Cruise Line Holdings Ltd ...

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies ...